The results demonstrated that these IL-15-modified CAR-NK cells maintained their anti-AML activity in a sustained manner, but this improvement in functionality was associated with significant systemic toxicities due to IL-15 secretion (73). The gene discussed is IL15; the disease is acute myeloid leukemia.